Actively Recruiting

Phase Not Applicable
Age: 13Years - 17Years
FEMALE
NCT04107870

Efficiency of Virtual Reality Exposure Therapy in the Management of Body Dysmorphic Disorders in Female Adolescents With Anorexia Nervosa

Led by CHU de Reims · Updated on 2023-03-08

40

Participants Needed

1

Research Sites

378 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Anorexia nervosa is defined in DSM V as a quantitative and qualitative dietary restriction resulting in significant weight loss, intense fear of weight gain, altered weight and body shape perception (body dysmorphic disorder) and low self-esteem influenced by weight or body shape. Body dysmorphic disorder is the most difficult symptom to manage in anorexia nervosa and its persistence is a factor associated with relapse. Virtual reality exposure therapy has proven its effectiveness in the management of post-traumatic stress disorder in the military and is a widely used therapy. The effectiveness of this treatment using new technologies has not yet been studied for the treatment of body dysmorphic disorder in anorexia nervosa and is not used routinely. It could represent an interesting alternative to the physical approach in psychomotor therapy, traditionally offered to patients suffering from anorexia nervosa. It is important to evaluate the effectiveness of virtual reality exposure therapy in the management of body dysmorphic disorder in patients with anorexia nervosa by comparing these two care techniques.

CONDITIONS

Official Title

Efficiency of Virtual Reality Exposure Therapy in the Management of Body Dysmorphic Disorders in Female Adolescents With Anorexia Nervosa

Who Can Participate

Age: 13Years - 17Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female adolescents aged 13 to 18
  • Diagnosed with anorexia nervosa of any type according to DSM-V
  • French as first language
  • Agreed to participate in the study
  • Parental consent obtained
  • Affiliated with a social security system
Not Eligible

You will not qualify if you...

  • Total aphagia
  • Body mass index below 14 kg/m² for those over 17 years old
  • BMI below 13.2 kg/m² for ages 15-16
  • BMI below 12.7 kg/m² for ages 13-14
  • Confusion
  • Bradycardia below 40/min or tachycardia
  • Blood pressure below 80/50 mmHg
  • Hypothermia below 35.5°C
  • Severe metabolic disorders including low potassium, sodium imbalance, or low phosphate levels
  • Acetonuria or hypoglycemia below 0.6 g/l
  • Elevated creatinine over 100 micromol/l
  • Liver cytolysis over 4 times normal
  • Low white blood cell count below 1000/mm3
  • Thrombocytopenia below 6000000/mm3
  • Suicide attempt within the last month
  • Receiving benzodiazepine treatment beyond prescribed limits
  • Psychotic disorders or psychoactive substance addiction as per MINI KID criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Damien JOLLY

Reims, France

Actively Recruiting

Loading map...

Research Team

J

Julien EUTROPE

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here